Table 1.

Socio-demographic features, clinical manifestations, and pharmacologic therapy in 144 patients with fibromyalgia syndrome.

Characteristic
Female, %	95.1
Age, mean (SD) years	50.2 (9.9)
median	49.5
Age groups, n
21–39	22
40–59	98
>60	24
Disease duration, mean (SD) years	4.9 (4.8)
Education (>14 years), %	52.1
Bone Mass Index, mean (SD)	28.7(5.4)
Mean (SD) tender point count	15.0 (4.7)
Current FMS symptom, %
Tiredness	96.5
Anorexia	22.2
Weight loss	13.0
Insomnia	67.4
Cognitive dysfunction	77.8
Headache	73.6
Shortness of breath	57.6
Constipation	55.5
Diarrhea	27.8
Increased Urinary frequency	54.1
Arthralgia	95.8
Subjective swelling	41.0
Morning stiffness	86.1
Myalgia	92.3
Paresthesia	81.9
Sicca symptoms	69.4
Dysmenorrhea (n = 69)	49.0
Cumulative comorbid condition, %
Depression	56.3
Anxiety	40.2
Osteoarthritis	59.0
Lumbar spine disease	39.5
Cervical spine disease	29.0
Osteoporosis	9.0
Peripheral neuropathy	19.4
Irritable bowel syndrome	29.2
Irritable bladder syndrome	25.0
Hyperlipidemia	43.0
Hypertension	35.4
Hypothyroidism	14.5
Diabetes mellitus	9.7
Bronchial asthma	15.2
Current pharmacologic therapy
Tricyclic antidepressants	15.2
SSRIs	23.6
SNRIs	41.7
Anticonvulsants	47.9
Muscle relaxants	28.5
NSAIDs	30.5

SD: Standard deviation; SSRIs: Serotonin selective reuptake inhibitors; SNRIs: Serotonin-norepinephrine reuptake inhibitors; NSAIDs: Non-steroidal anti-inflammatory drugs